Literature DB >> 9798076

Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.

R S Kern1, M F Green, B D Marshall, W C Wirshing, D Wirshing, S McGurk, S R Marder, J Mintz.   

Abstract

BACKGROUND: The present study compared the effects of risperidone vs. haloperidol on reaction time, manual dexterity, and two types of motor learning in a sample of treatment-resistant schizophrenia patients.
METHODS: Fifty-six DSM-III-R diagnosed schizophrenia inpatients participated in a randomized, double-blind comparison of risperidone vs. haloperidol. Measures of reaction time, manual dexterity, motor sequence learning, and gross motor learning were administered at baseline, after 4 weeks of fixed-dose medication, and after 4 weeks of flexible-dose medication.
RESULTS: The results indicated that patients receiving risperidone showed greater improvement in reaction time and manual dexterity than patients receiving haloperidol. After covarying symptom changes and movement disorder ratings, the results remained significant. The two treatment groups did not differ on either measure of motor learning.
CONCLUSIONS: The differences in performance in reaction time and manual dexterity may be due to a specific beneficial effect of risperidone, as opposed to a general reduction in extrapyramidal symptom liability, compared to haloperidol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798076     DOI: 10.1016/s0006-3223(98)00088-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  14 in total

1.  Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.

Authors:  Blanka Kores Plesnicar; Bojan Zalar; Martina Tomori; Ivan Krajnc
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

Review 2.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

Review 3.  The cytokine model of schizophrenia: emerging therapeutic strategies.

Authors:  Ragy R Girgis; Samhita S Kumar; Alan S Brown
Journal:  Biol Psychiatry       Date:  2013-12-11       Impact factor: 13.382

4.  More than just tapping: index finger-tapping measures procedural learning in schizophrenia.

Authors:  Felipe N Da Silva; Farzin Irani; Jan Richard; Colleen M Brensinger; Warren B Bilker; Raquel E Gur; Ruben C Gur
Journal:  Schizophr Res       Date:  2012-02-16       Impact factor: 4.939

Review 5.  Mouse pharmacological models of cognitive disruption relevant to schizophrenia.

Authors:  Jared W Young; Susan B Powell; Mark A Geyer
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

Review 6.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Visuospatial imagery and working memory in schizophrenia.

Authors:  Natasha L Matthews; Kathleen P Collins; Katharine N Thakkar; Sohee Park
Journal:  Cogn Neuropsychiatry       Date:  2013-05-24       Impact factor: 1.871

8.  Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia.

Authors:  Margret S H Harris; Courtney L Wiseman; James L Reilly; Matcheri S Keshavan; John A Sweeney
Journal:  Neuropsychopharmacology       Date:  2008-06-04       Impact factor: 7.853

Review 9.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

10.  Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.

Authors:  Scot E Purdon; Neil Woodward; Stacy R Lindborg; Emmanuel Stip
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.